Stifel Nicolaus Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Enliven Therapeutics (NASDAQ:ELVN) had its price target hoisted by equities researchers at Stifel Nicolaus from $60.00 to $80.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 58.98% from the company’s previous close.

ELVN has been the topic of a number of other research reports. Guggenheim began coverage on shares of Enliven Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price on the stock. The Goldman Sachs Group lifted their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, May 8th. HC Wainwright increased their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.83.

Enliven Therapeutics Trading Down 0.8%

NASDAQ ELVN traded down $0.43 during mid-day trading on Wednesday, hitting $50.32. The company’s stock had a trading volume of 65,736 shares, compared to its average volume of 1,333,895. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of -30.22 and a beta of 0.29. The company’s 50 day simple moving average is $42.34 and its 200 day simple moving average is $32.98. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $52.39.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. As a group, research analysts forecast that Enliven Therapeutics will post -1.71 EPS for the current year.

Insiders Place Their Bets

In other news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. The trade was a 16.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at $2,233,800. This trade represents a 10.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. HighVista Strategies LLC boosted its stake in Enliven Therapeutics by 83.1% in the third quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock valued at $5,304,000 after acquiring an additional 117,619 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Enliven Therapeutics during the 3rd quarter worth approximately $334,000. Spruce Street Capital LP bought a new stake in shares of Enliven Therapeutics in the 4th quarter worth approximately $6,870,000. Capricorn Fund Managers Ltd bought a new stake in shares of Enliven Therapeutics in the 1st quarter worth approximately $14,480,000. Finally, Seven Fleet Capital Management LP purchased a new position in Enliven Therapeutics in the fourth quarter valued at approximately $180,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.